{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:35:44Z","timestamp":1773758144887,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.1378\/chest.122.4.1292","type":"journal-article","created":{"date-parts":[[2003,6,13]],"date-time":"2003-06-13T20:09:19Z","timestamp":1055534959000},"page":"1292-1298","source":"Crossref","is-referenced-by-count":20,"title":["Short-Course Rifamycin and Pyrazinamide Treatment for Latent Tuberculosis Infection in Patients with HIV Infection"],"prefix":"10.1016","volume":"122","author":[{"given":"Masahiro","family":"Narita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Kellman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana L.","family":"Franchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie E.","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena S.","family":"Hollender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ashkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1378\/chest.122.4.1292_bib1","unstructured":"Centers for Disease Control and Prevention. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR Morb Mortal Wkly Rep 1998; 47(RR-20):1\u201358"},{"key":"10.1378\/chest.122.4.1292_bib2","doi-asserted-by":"crossref","unstructured":"American Thoracic Society\/Centers for Disease Control and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society. Am J Respir Crit Care Med 1994; 149:1359\u20131374","DOI":"10.1164\/ajrccm.149.5.8173779"},{"key":"10.1378\/chest.122.4.1292_bib3","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.283.11.1445","volume":"283","author":"Gordin","year":"2000","journal-title":"JAMA"},{"key":"10.1378\/chest.122.4.1292_bib4","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0140-6736(97)06532-X","article-title":"Randomised trial of isoniazid vs rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection","volume":"351","author":"Halsey","year":"1998","journal-title":"Lancet"},{"key":"10.1378\/chest.122.4.1292_bib5","unstructured":"Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Morb Mortal Wkly Rep 2000; 49(RR-6):1\u201351"},{"key":"10.1378\/chest.122.4.1292_bib6","unstructured":"Centers for Disease Control and Prevention. HIV\/AIDS Surveill Report 2001; 12:8\u201310"},{"key":"10.1378\/chest.122.4.1292_bib7","unstructured":"2000 census, Available at: www.census.gov. Accessed September 17, 2002"},{"key":"10.1378\/chest.122.4.1292_bib8","unstructured":"UNAIDS, Report on the global HIV\/AIDS epidemic, 2000. Available at: www.unaids.org\/epidemic_update\/report_july02\/index.html. Accessed September 19, 2002"},{"key":"10.1378\/chest.122.4.1292_bib9","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","article-title":"Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance Monitoring Project","volume":"282","author":"Dye","year":"1999","journal-title":"JAMA"},{"key":"10.1378\/chest.122.4.1292_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1164\/ajrccm.159.1.9807020","article-title":"A tuberculin screening and isoniazid preventive therapy program in an inner-city population","volume":"159","author":"Bock","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.122.4.1292_bib11","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198903023200901","article-title":"A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection","volume":"320","author":"Selwyn","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1378\/chest.122.4.1292_bib12","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-199818000-00014","article-title":"Twice weekly tuberculosis preventive therapy in HIV infection in Zambia","volume":"12","author":"Mwinga","year":"1998","journal-title":"AIDS"},{"key":"10.1378\/chest.122.4.1292_bib13","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1164\/ajrccm.157.6.9711039","article-title":"Antituberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus","volume":"157","author":"Ungo","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.122.4.1292_bib14","unstructured":"Centers for Disease Control, and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection\u2013New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep 2001; 50:289\u2013291"},{"key":"10.1378\/chest.122.4.1292_bib15","unstructured":"Centers for Disease Control and Prevention update. Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society\/CDC recommendations\u2013United States, 2001. MMWR Morb Mortal Wkly Rep 2001; 50:733\u2013735"},{"key":"10.1378\/chest.122.4.1292_bib16","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1378\/chest.119.3.833","article-title":"Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates","volume":"119","author":"Bock","year":"2001","journal-title":"Chest"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215377977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215377977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T16:31:41Z","timestamp":1553099501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215377977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["S0012369215377977"],"URL":"https:\/\/doi.org\/10.1378\/chest.122.4.1292","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}